Raloxifene administration in post-menopausal women with osteoporosis: Effect of different BsmI vitamin D receptor genotypes

Stefano Palomba, Fabio Giuliano Numis, Giuseppe Mossetti, Domenico Rendina, Pietro Vuotto, Tiziana Russo, Fulvio Zullo, Carmine Nappi, Vincenzo Nunziata

Research output: Contribution to journalArticle

Abstract

Background: The vitamin D receptor (VDR) gene polymorphism has been considered a factor influencing the effectiveness of the anti-osteoporotic treatments. The aim of this study was to correlate the effectiveness of raloxifene treatment in post-menopausal women with osteoporosis to BsmI VDR genotypes. Methods: Between January and August 2000, 75 Italian osteoporotic women were enrolled and treated with raloxifene at a dose of 60 mg/day. At entry and after 1 year of treatment, lumbar bone mineral density (BMD), serum osteocalcin (OC) and urinary creatinine-corrected free deoxypyridinoline (DPD) levels were evaluated. DNA was extracted from blood and analysed with restriction endonuclease BsmI for VDR gene. Results: After treatment, a significant increase in lumbar BMD and a significant reduction in serum OC and urinary DPD levels were observed. The percentage of change (mean ± SD) in lumbar BMD, and in serum OC and urinary DPD levels was significantly different in homozygous bb (1.58 ± 0.80, -5.15 ± 2.36 and -7.71 ± 2.89 for BMD, OC and DPD respectively) in comparison with BB (4.13 ± 2.26, -13.59 ± 4.68 and -15.16 ± 4.65 for BMD, OC and DPD respectively) BsmI VDR genotypes. Heterozygous Bb VDR patients showed an intermediate percentage (mean ± SD) of BMD, serum OC and urinary DPD change (2.49 ± 1.54, -8.69 ± 2.60 and -10.52 ± 2.56 for BMD, OC and DPD respectively) not significantly different in comparison with homozygous BB and bb. Conclusions: In post-menopausal women with osteoporosis the effectiveness of raloxifene treatment on bone metabolism seems to be controlled by different BsmI VDR genotypes.

Original languageEnglish
Pages (from-to)192-198
Number of pages7
JournalHuman Reproduction
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 1 2003

    Fingerprint

Keywords

  • Bone mineral density
  • Osteoporosis
  • Post-menopause
  • Raloxifene
  • Vitamin D receptor gene polymorphisms

ASJC Scopus subject areas

  • Physiology
  • Developmental Biology
  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Palomba, S., Numis, F. G., Mossetti, G., Rendina, D., Vuotto, P., Russo, T., Zullo, F., Nappi, C., & Nunziata, V. (2003). Raloxifene administration in post-menopausal women with osteoporosis: Effect of different BsmI vitamin D receptor genotypes. Human Reproduction, 18(1), 192-198. https://doi.org/10.1093/humrep/deg031